Slide 1: BONESUPPORT Q3 (2024) Report
BONESUPPORT Q3 (2024) Report October 24th, 2024 Emil Billbäck, CEO Håkan Johansson, CFO
Slide 2: Disclaimer
DISCLAIMER This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDIN
Slide 3: BONESUPPORT – Third quarter report 2024
BONESUPPORT – Third quarter report 2024 Q3 2024: • Net sales SEK 238 m, growth: +50% versus Q3 2023, (+54% in constant exchange rates, CER) • Operating result (before accounting effects of incentive programs): SEK 48 m (SEK 25 m) • Reported EBIT: SEK 41 m (SEK 15 m) • Strong positive cash flow • SOL
Slide 4: Strong launch momentum for CERAMENT G in the US
Strong launch momentum for CERAMENT G in the US • CERAMENT G in the US reaching SEK 134 m in the quarter • Launch conference for Open Trauma indication at OTA in Montreal, Oct 23rd - 26th • Total antibiotic eluting CERAMENT grew with 81% versus Q3 2023 CBVF= CERAMENT Bone Void Filler CG = CERAMENT G
Slide 5: North America: Strong surgeon preference and increasing peer-to-peer referrals
North America Strong surgeon preference and increasing peer-to-peer referrals Q3 2024 • Sales of SEK 192 m, growth of 59% over Q3 2023 (growth of 63% in constant exchange rate, CER) Highlights in quarter: • NTAP submission for Open Trauma • CERAMENT G sales of SEK 134 m • Progressing market access t
Slide 6: EUROW: Market share gains fuels sales performance
EUROW Market share gains fuels sales performance Q3 2024 • Sales of SEK 46 m, growth of 22% vs Q3 2023, (growth of 21% in constant exchange rates, CER) • Seasonality impact Highlights • CERAMENT V approved (MDSAP) for Canada. Hire resources for conversion to hybrid market • SOLARIO study met its pri
Slide 7: SOLARIO – Game changing evidence for local antibiotics
SOLARIO – Game changing evidence for local antibiotics Study summary1 110 Number of patients • Randomized controlled multicenter trial with 500 adult patients with orthopedic infections 100 • Surgically treated with antibiotic-eluting bone substitute materials such as CERAMENT G and CERAMENT V 90 St
Slide 8: BONESUPPORT Q3 (2024) Report – Financial Report
BONESUPPORT Q3 (2024) Report Financial Report 8
Slide 9: Q3 2024 net sales SEK 237.5 m
Q3 2024 net sales SEK 237.5 m SEK m • NA: 59 percent reported growth. 63 percent growth in CER • EUROW: 22 percent reported growth. 21 percent growth CER • Low impact from currency movements 9
Slide 10: North America and EUROW net sales and gross margin
North America +59% EUROW +22% (+63% CER) (+21% CER) Net sales Net sales Q3-24 Q3-24 North America 2024 2023 EUROW 2024 2023 SEK m Q3 Q2 Q1 Q4 Q3 SEK m Q3 Q2 Q1 Q4 Q3 Net Sales 192,0 173,0 141,5 131,6 121,0 Net Sales 45,5 46,8 43,0 41,1 37,2 Gross profit 181,9 165,7 134,8 125,1 114,4 Gross profit 37,
Slide 11: Investments in commercial structure and R&D impacting the quarter
Investments in commercial structure and R&D impacting the quarter Key Figures 2024 2023 2022 SEK m Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Selling expenses 65,5 67,6 59,7 59,6 53,5 55,0 49,0 46,8 Sales Commissions and fees 65,5 62,2 48,2 44,4 42,7 37,2 29,9 28,1 Research and Development expenses 19,7 20,3 14,1 17,6
Slide 12: 54% Sales growth and doubled adjusted operating profit
54% Sales growth and doubled adjusted operating profit Key Figures 2024 2023 2022 SEK m Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Net Sales 237,5 219,8 184,4 172,7 158,2 140,4 119,7 103,2 Gross Margin (%) 92,9 92,3 92,6 91,8 92,1 91,3 90,5 91,5 Operating profit 41,0 28,7 32,3 -8,0 14,9 6,0 0,8 -19,3 Adj. Operating pr
Slide 13: BONESUPPORT Q3 (2024) Report
BONESUPPORT Q3 (2024) Report • 50% sales growth (53% in CER) • 48 mSEK EBIT (before incentive cost) • Milestone SOLARIO study results • Strong performance for CERAMENT G USA • Progressing pre-clinical spine studies 13